Nifty
:
18633.85
Sensex
:
62969.13
35.20 (0.19%)
122.75 (0.20%)
Nifty
Sensex
:
:
18633.85
62969.13
35.20 (0.19%)
122.75 (0.20%)

Caplin Point Laboratories Ltd.

Pharmaceuticals & Drugs - Global

Rating :
63/99

BSE: 524742 | NSE: CAPLIPOINT

NSE BSE
735.90
29-May-2023
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 756.00
  • 770.00
  • 731.55
  • 736.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  162699
  •  1222.54
  •  856.80
  •  575.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 5,586.70
  • 14.89
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,124.21
  • 0.27%
  • 2.98

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 70.66%
  • 1.83%
  • 18.73%
  • FII
  • DII
  • Others
  • 2.36%
  • 0.57%
  • 5.85%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 18.65
  • 13.72

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 15.10
  • 8.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 15.67
  • 11.73

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.75
  • 17.86
  • 18.02

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.03
  • 4.52
  • 3.87

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.99
  • 11.81
  • 12.04

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Net Sales
389.28
339.24
14.75%
372.07
326.20
14.06%
359.05
303.53
18.29%
346.33
300.44
15.27%
Expenses
265.35
239.30
10.89%
262.70
225.24
16.63%
253.47
202.36
25.26%
244.15
207.83
17.48%
EBITDA
123.93
99.94
24.00%
109.37
100.96
8.33%
105.58
101.17
4.36%
102.18
92.61
10.33%
EBIDTM
31.84%
29.46%
29.39%
30.95%
29.41%
33.33%
29.50%
30.82%
Other Income
11.40
11.51
-0.96%
14.15
9.54
48.32%
16.48
8.49
94.11%
13.94
9.21
51.36%
Interest
0.23
0.08
187.50%
0.36
0.14
157.14%
0.14
0.21
-33.33%
0.06
0.27
-77.78%
Depreciation
11.13
11.45
-2.79%
11.43
11.70
-2.31%
11.46
11.72
-2.22%
10.97
12.03
-8.81%
PBT
123.97
99.92
24.07%
111.73
98.66
13.25%
110.46
97.73
13.03%
105.09
89.52
17.39%
Tax
22.81
19.09
19.49%
14.35
19.38
-25.95%
18.42
20.91
-11.91%
18.78
17.99
4.39%
PAT
101.16
80.83
25.15%
97.38
79.28
22.83%
92.04
76.82
19.81%
86.31
71.53
20.66%
PATM
25.99%
23.83%
26.17%
24.30%
25.63%
25.31%
24.92%
23.81%
EPS
13.45
10.43
28.95%
12.84
9.89
29.83%
12.09
9.91
22.00%
11.21
9.37
19.64%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Net Sales
1,466.73
1,269.41
1,061.29
863.20
648.69
539.84
401.65
238.72
251.77
173.09
127.03
Net Sales Growth
15.54%
19.61%
22.95%
33.07%
20.16%
34.41%
68.25%
-5.18%
45.46%
36.26%
 
Cost Of Goods Sold
663.21
557.51
471.74
413.16
288.78
238.18
184.93
121.16
135.62
102.58
84.45
Gross Profit
803.52
711.90
589.55
450.04
359.91
301.66
216.72
117.56
116.15
70.50
42.58
GP Margin
54.78%
56.08%
55.55%
52.14%
55.48%
55.88%
53.96%
49.25%
46.13%
40.73%
33.52%
Total Expenditure
1,025.67
874.88
737.04
603.13
416.84
344.52
276.84
174.51
192.06
136.90
104.68
Power & Fuel Cost
-
21.40
16.36
14.81
13.76
10.98
9.91
7.56
8.61
3.07
1.12
% Of Sales
-
1.69%
1.54%
1.72%
2.12%
2.03%
2.47%
3.17%
3.42%
1.77%
0.88%
Employee Cost
-
114.74
101.97
67.15
45.58
37.61
29.71
17.92
18.24
12.63
7.69
% Of Sales
-
9.04%
9.61%
7.78%
7.03%
6.97%
7.40%
7.51%
7.24%
7.30%
6.05%
Manufacturing Exp.
-
82.01
69.85
68.23
43.49
37.11
28.56
14.33
16.04
7.42
3.07
% Of Sales
-
6.46%
6.58%
7.90%
6.70%
6.87%
7.11%
6.00%
6.37%
4.29%
2.42%
General & Admin Exp.
-
49.16
38.53
25.50
20.82
12.27
13.78
8.15
7.97
6.54
4.67
% Of Sales
-
3.87%
3.63%
2.95%
3.21%
2.27%
3.43%
3.41%
3.17%
3.78%
3.68%
Selling & Distn. Exp.
-
27.51
18.03
9.95
2.08
5.92
9.41
2.29
2.85
1.46
1.02
% Of Sales
-
2.17%
1.70%
1.15%
0.32%
1.10%
2.34%
0.96%
1.13%
0.84%
0.80%
Miscellaneous Exp.
-
22.55
20.56
4.33
2.33
2.45
0.55
3.10
2.72
3.19
1.02
% Of Sales
-
1.78%
1.94%
0.50%
0.36%
0.45%
0.14%
1.30%
1.08%
1.84%
2.09%
EBITDA
441.06
394.53
324.25
260.07
231.85
195.32
124.81
64.21
59.71
36.19
22.35
EBITDA Margin
30.07%
31.08%
30.55%
30.13%
35.74%
36.18%
31.07%
26.90%
23.72%
20.91%
17.59%
Other Income
55.97
38.89
27.93
41.33
19.03
12.67
9.96
3.66
3.03
3.72
2.10
Interest
0.79
0.70
1.59
0.32
0.58
0.61
0.52
0.34
0.97
0.68
0.77
Depreciation
44.99
46.90
36.97
31.62
23.43
19.00
13.30
7.48
8.38
3.54
1.54
PBT
451.25
385.82
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
22.14
Tax
74.36
77.37
62.19
54.38
50.32
43.74
25.44
14.28
12.26
9.76
8.12
Tax Rate
16.48%
20.05%
19.83%
20.18%
22.18%
23.22%
21.03%
23.78%
22.96%
27.35%
36.68%
PAT
376.89
299.84
242.27
215.00
176.56
144.78
95.61
45.77
41.04
25.85
13.98
PAT before Minority Interest
376.17
308.45
251.43
215.08
176.56
144.63
95.50
45.77
41.13
25.93
14.02
Minority Interest
-0.72
-8.61
-9.16
-0.08
0.00
0.15
0.11
0.00
-0.09
-0.08
-0.04
PAT Margin
25.70%
23.62%
22.83%
24.91%
27.22%
26.82%
23.80%
19.17%
16.30%
14.93%
11.01%
PAT Growth
22.18%
23.76%
12.68%
21.77%
21.95%
51.43%
108.89%
11.53%
58.76%
84.91%
 
EPS
49.66
39.50
31.92
28.33
23.26
19.08
12.60
6.03
5.41
3.41
1.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Shareholder's Funds
1,483.93
1,185.83
947.91
632.91
363.83
224.76
128.14
93.19
61.74
43.14
Share Capital
89.74
89.71
89.71
51.05
15.12
15.12
15.11
15.11
15.11
15.11
Total Reserves
1,385.24
1,081.33
848.76
575.01
345.42
209.56
111.40
78.08
46.63
28.03
Non-Current Liabilities
12.55
17.39
24.86
23.42
27.86
19.90
13.69
10.39
10.42
8.66
Secured Loans
0.00
0.00
0.02
0.29
0.32
0.48
0.73
0.88
2.07
3.48
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
8.48
5.69
5.23
0.13
0.00
0.40
1.63
0.82
0.81
0.38
Current Liabilities
207.68
142.85
144.32
86.11
108.67
113.36
125.04
124.97
107.58
83.01
Trade Payables
163.18
88.50
64.14
60.47
94.23
78.60
55.71
41.56
31.50
25.64
Other Current Liabilities
41.94
51.87
79.28
24.20
13.86
33.09
60.39
72.11
66.42
50.85
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.05
0.05
0.05
Short Term Provisions
2.56
2.48
0.91
1.44
0.58
1.67
8.94
11.25
9.60
6.47
Total Liabilities
1,730.11
1,363.61
1,125.75
742.52
500.45
358.38
267.14
228.82
179.92
134.90
Net Block
286.57
305.34
272.50
226.84
169.48
151.83
144.23
113.13
102.24
32.71
Gross Block
445.74
422.58
354.79
271.51
231.79
195.15
180.76
142.71
123.06
50.06
Accumulated Depreciation
159.17
117.24
82.29
44.67
62.31
43.31
36.53
29.58
20.82
17.36
Non Current Assets
432.29
349.04
303.23
248.83
196.34
179.16
148.61
146.95
131.30
96.21
Capital Work in Progress
17.73
13.88
20.12
9.70
15.29
3.42
0.23
30.63
24.54
48.98
Non Current Investment
37.01
0.66
0.56
0.33
0.33
13.24
0.44
0.45
0.44
1.19
Long Term Loans & Adv.
89.90
7.92
10.05
11.95
11.23
10.67
3.71
2.75
3.67
10.83
Other Non Current Assets
1.08
21.24
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,297.82
1,014.57
822.53
493.69
304.11
179.22
118.53
81.87
48.61
38.70
Current Investments
51.97
10.54
60.23
69.62
46.34
4.20
0.00
0.00
0.00
0.00
Inventories
227.31
179.01
238.23
37.45
28.46
22.29
18.81
13.66
9.79
10.42
Sundry Debtors
320.06
279.36
228.96
159.81
125.88
33.02
7.95
5.66
0.09
0.86
Cash & Bank
462.99
438.33
223.43
152.99
79.28
93.07
68.10
45.37
26.82
16.84
Other Current Assets
235.49
20.25
14.87
9.22
24.16
26.63
23.67
17.18
11.90
10.57
Short Term Loans & Adv.
221.88
87.08
56.81
64.61
17.28
19.31
12.58
11.08
8.16
5.61
Net Current Assets
1,090.14
871.72
678.21
407.58
195.44
65.86
-6.51
-43.10
-58.97
-44.31
Total Assets
1,730.11
1,363.61
1,125.76
742.52
500.45
358.38
267.14
228.82
179.91
134.91

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Cash From Operating Activity
336.75
268.61
44.68
83.42
66.49
67.61
42.40
49.88
59.83
31.95
PBT
385.82
313.62
269.46
226.88
188.38
120.95
60.05
53.39
35.69
22.14
Adjustment
30.44
23.09
7.09
19.12
14.84
8.61
3.87
6.21
2.14
-0.21
Changes in Working Capital
1.99
-1.96
-177.11
-120.06
-100.38
-38.39
-5.13
1.96
29.32
15.81
Cash after chg. in Working capital
418.25
334.75
99.44
125.94
102.84
91.16
58.78
61.56
67.15
37.75
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-81.50
-66.14
-54.76
-42.51
-36.35
-23.55
-16.38
-11.67
-7.32
-5.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-270.94
-29.44
-54.50
-100.46
-69.02
-36.11
-5.72
-22.66
-43.89
-45.44
Net Fixed Assets
-3.66
-35.46
-43.65
58.45
-48.43
-19.56
-7.66
-25.72
-48.50
-43.00
Net Investments
-115.52
46.59
-27.53
-120.03
-29.43
-17.35
0.01
-0.90
0.75
-0.05
Others
-151.76
-40.57
16.68
-38.88
8.84
0.80
1.93
3.96
3.86
-2.39
Cash from Financing Activity
-40.71
-23.98
79.77
89.79
-11.60
-6.74
-13.95
-8.67
-5.96
-1.48
Net Cash Inflow / Outflow
25.10
215.19
69.94
72.76
-14.13
24.76
22.73
18.55
9.99
-14.97
Opening Cash & Equivalents
435.72
220.77
150.65
77.17
91.31
66.55
45.37
26.82
16.84
31.80
Closing Cash & Equivalent
460.73
435.72
220.77
150.65
77.17
91.31
68.10
45.37
26.82
16.84

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Jun 15
Jun 14
Jun 13
Book Value (Rs.)
184.75
144.94
114.21
78.03
47.69
29.73
16.25
11.84
7.68
5.22
ROA
19.94%
20.20%
23.02%
28.41%
33.68%
30.54%
18.46%
20.12%
16.48%
11.59%
ROE
24.71%
25.65%
29.58%
37.14%
49.43%
54.97%
43.13%
55.78%
53.24%
40.49%
ROCE
28.77%
28.82%
33.35%
45.59%
64.08%
69.03%
55.41%
71.11%
68.99%
56.69%
Fixed Asset Turnover
2.92
2.73
2.76
2.58
2.53
2.14
1.48
1.89
2.00
2.73
Receivable days
86.18
87.41
82.19
80.37
53.72
18.62
10.40
4.17
1.00
11.66
Inventory Days
58.42
71.75
58.28
18.54
17.16
18.68
24.83
17.00
21.31
24.06
Payable days
82.39
59.05
28.33
65.76
89.68
88.17
103.48
69.75
79.69
85.60
Cash Conversion Cycle
62.21
100.11
112.15
33.15
-18.80
-50.88
-68.24
-48.58
-57.39
-49.89
Total Debt/Equity
0.00
0.01
0.04
0.00
0.00
0.00
0.02
0.02
0.06
0.12
Interest Cover
552.17
198.25
843.86
391.22
309.72
235.08
179.35
56.11
53.29
29.73

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Caplin Point Lab - Quarterly Results
    27th May 2023, 12:43 PM

    Read More
  • Caplin Point Laboratories’ arm gets USFDA’s nod for Ketorolac Tromethamine Injection
    12th May 2023, 11:57 AM

    Ketorolac Tromethamine Injection USP had US sales of around $53 million for the 12-month period ending December 2022

    Read More
  • Caplin Point to sell Caplin Point Laboratories Colombia SAS to Caplin Point Far East
    29th Mar 2023, 18:10 PM

    Pursuant to execution of the Share Purchase Agreement and transfer of shares, Caplin Point Laboratories Colombia SAS - Colombia will cease to be a subsidiary of the Company

    Read More
  • Caplin Point Laboratories’ arm gets USFDA’s nod for Thiamine Hydrochloride Injection
    8th Mar 2023, 14:47 PM

    Thiamine Hydrochloride Injection is effective in the treatment of Thiamine (Vitamin B1) deficiency or beriberi

    Read More
  • Caplin Point Laboratories’ arm gets USFDA’s approval for Rocuronium Bromide Injection
    3rd Mar 2023, 12:39 PM

    Rocuronium Bromide Injection is a neuromuscular blocking agent, indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.